机构：[1]Department of Gastroenterology, Wuhan Third Hospital, Tongren Hospital of Wuhan University, No 241, Pengliuyang Road, Wuchang District, Wuhan 430060, China,[2]Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China,[3]Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China,[4]Department of Medical Laboratory, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China,[5]Cancer Research Institute of Wuhan, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China[6]Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Pancreatic cancer (PC) is a highly invasive tumor with early metastasis and poor prognosis, yet the mechanisms for tumor progression have not been fully elucidated. Emerging evidence indicates that microRNA-331-3p (miR-331-3p) plays an important role in the progression of diverse human cancers. Here, we found that miR-331-3p was significantly upregulated in tumor specimens of PC patients and PC cell lines. Functional studies showed that downregulation of miR-331-3p inhibited PC cell proliferation and epithelial-mesenchymal transition (EMT)-mediated metastasis in vitro. Furthermore, suppression of tumorigenicity 7 like (ST7L) was identified as a novel target gene of miR-331-3p. Tumor promotion effects of miR-331-3p were partially reversed by ST7L re-expression. In addition, miR-331-3p antagomir suppressed PC tumor growth and metastasis via upregulation of ST7L in xenograft mice. In summary, these results demonstrate that miR-331-3p is a tumor-promoting microRNA (miRNA) in PC cells and a promising biomarker for PC.
基金：
Key Project of Natural
Sciences Foundation of Hubei Province (2015CFA078), the Natural
Sciences Foundation of Hubei Province (2018CFB339), Science and
technology support program (foreign scientific and technological
cooperation) of Hubei Province (2015BHE022) and the Yellow
Crane Talent Plan Foundation and Research Fund of Wuhan
Public Health Bureau (WX14C13 and WX14B10).
第一作者机构：[1]Department of Gastroenterology, Wuhan Third Hospital, Tongren Hospital of Wuhan University, No 241, Pengliuyang Road, Wuchang District, Wuhan 430060, China,[2]Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China,[3]Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China,
共同第一作者：
通讯作者：
通讯机构：[4]Department of Medical Laboratory, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China,[5]Cancer Research Institute of Wuhan, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
推荐引用方式(GB/T 7714)：
Chen Xiaoli,Luo Hesheng,Li Xiaoyi,et al.miR-331-3p functions as an oncogene by targeting ST7L in pancreatic cancer[J].CARCINOGENESIS.2018,39(8):1006-1015.doi:10.1093/carcin/bgy074.
APA：
Chen, Xiaoli,Luo, Hesheng,Li, Xiaoyi,Tian, Xia,Peng, Bo...&Huang, Xiaodong.(2018).miR-331-3p functions as an oncogene by targeting ST7L in pancreatic cancer.CARCINOGENESIS,39,(8)
MLA：
Chen, Xiaoli,et al."miR-331-3p functions as an oncogene by targeting ST7L in pancreatic cancer".CARCINOGENESIS 39..8(2018):1006-1015
